E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Myeloid Leukaemia |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and efficacy of subcutaneous administration of homoharringtonine (HHT) (omacetaxine) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have the T315I BCR-ABL gene mutation |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female patients, age 18 years or older 2. Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in either chronic, accelerated, or blast phase. a) Patients in accelerated phase will meet one or more of the following criteria: >=15% - <30% blasts in peripheral blood or bone marrow, >=30% blasts + promyelocytes in peripheral blood or bone marrow, >=20% basophils in peripheral blood or bone marrow; platelet count <100 x 109/L unrelated to therapy or clonal evolution. b) CML in blast phase will be defined as >=30% blasts in the bone marrow or presence of extramedullary disease. c) All other patients will be considered to have chronic phase CML 3. The patient will have the T315I BCR-ABL gene mutation. 4. Patients must have completed all previous anti-leukemic therapy for at least 2 weeks, prior to the first planned dose of HHT, except as noted below, and must have fully recovered from side effects of a previous therapy, unless disease progression necessitates early therapy. In patients with rapidly proliferating disease, hydroxyurea may be administered during the first two cycles of treatment, if clinically indicated, to control disease. In such cases, complete hematologic response (CHR) must be sustained for >= 4 weeks for accelerated and blast phase CML and for >= 8 weeks for chronic phase CML, following the discontinuation of hydroxyurea, to be considered as a CHR. Patients may receive anagrelide for up to 28 days (in countries where the product is registered). Leukapheresis is allowed up to 24 hours prior to registration. 5. Bilirubin ≤ 2.0 times upper limit of normal (ULN) ALT ≤ 3 times ULN Creatinine ≤ 1.5 times ULN 6. ECOG performance status 0-2.
|
|
E.4 | Principal exclusion criteria |
1. NYHA class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia and requiring therapy, uncontrolled hypertension or congestive heart failure. 2. Myocardial infarction in the previous 12 weeks. 3. Other concurrent illness which would preclude study conduct and assessment, including but not limited to another active malignancy (excluding squamous or basal cell skin cancer and in situ cervical cancer), uncontrolled and active infection, positive HIV status or positive HTLV I/II status. 4. Pregnant or lactating. 5. Any medical or psychiatric condition, which may compromise the ability to give written informed consent or to comply with the study protocol. 6. Lymphoid Ph+ blast crisis
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the proportion of patients achieving a clinical response, defined for each patient subpopulation, as follows: Chronic phase CML: Achievement of a complete hematologic response (CHR) or major cytogenetic response (complete or partial response, up to 35% Ph+ metaphases). The response must last >= 8 weeks to be considered meaningful. Accelerated phase CML: Achievement of either a complete hematologic response (CHR), no evidence of leukemia (NEL), or return to chronic phase CML. The response must last >=4 weeks to be considered meaningful. Cytogenetic responses will also be evaluated. Blast phase CML: Achievement of either a complete hematologic response (CHR), no evidence of leukemia (NEL), or return to chronic phase CML. The response must last >= 4 weeks to be considered meaningful. Cytogenetic responses will also be evaluated.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |